Humira now licensed for psoriasis treatment in children

Humira (adalimumab) is now licensed for the treatment of severe chronic plaque psoriasis in children.

A child's arm displaying characteristic psoriatic plaques. | SCIENCE PHOTO LIBRARY
A child's arm displaying characteristic psoriatic plaques. | SCIENCE PHOTO LIBRARY

Humira can now be used in children from 4 years old with severe chronic plaque psoriasis who are inappropriate for, or have not responded sufficiently to topical therapies and phototherapies. The recommended dose is based on weight and administered subcutaneously weekly for the first two weeks then every other week. 

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Fourth formoterol/budesonide dry powder inhaler launched

Fourth formoterol/budesonide dry powder inhaler launched

WockAIR is a further alternative to Symbicort Turbohaler.

Deleted products - live tracker

Deleted products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products removed...

New products - live tracker

New products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products added...

Don't prescribe antibiotics for childhood chest infections, GPs advised

Don't prescribe antibiotics for childhood chest infections, GPs advised

Clinicians should not prescribe antibiotics for most...